Skip to main content
Home
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
      • Specialties
        • Vaccines & Infectious Diseases
        • Ophthalmology
        • Clinical Neuroscience
        • Rare Disease
        • Cell & Gene Therapy
        • Government
      • Additional Specialties
        • Hematology
        • Oncology
        • Maternal & Child Health
        • Medical Devices
      • Clinical Services
        • Biostatistics
        • Clinical Data Management
        • Clinical Research Services
        • Clinical Trial Management
        • Global Regulatory Affairs
        • Pharmacovigilance & Medical Monitoring
    • Veridix - Tech & AI
      • eClinical Platform
        • EDC
        • Decentralized Clinical Trials
        • Health Navigator
        • RTSM
        • eCOA / ePRO
      • AI Agents
        • Biostats and Analysis Agent
        • Data Management Agent
        • Document Authoring
      • GlobalTrace
      • Analytics & Reporting
        • Clinical Pipelines
        • VERA
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us

Breadcrumb

  1. Emmes Group

Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group.

Go back to Resources

Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001).

Go back to Resources

First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001).

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Fetal antiepileptic drug exposure: Adaptive and emotional/behavioral functioning at age 6years.

Go back to Resources

Fetal antiepileptic drug exposure: Adaptive and emotional/behavioral functioning at age 6years.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Evaluation of the Mercy TAPE: performance against the standard for pediatric weight estimation.

Go back to Resources

Evaluation of the Mercy TAPE: performance against the standard for pediatric weight estimation.

Authors:

Volume:

Pagination:

Issue:

Journal:

PMID:

URL:

DOI:

Keywords:

Abstract:

Go back to Resources

Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women.

Go back to Resources

Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Determining Population and Developmental Pharmacokinetics of Metronidazole using Plasma and Dried Blood Spot Samples from Premature Infants

Go back to Resources

Determining Population and Developmental Pharmacokinetics of Metronidazole using Plasma and Dried Blood Spot Samples from Premature Infants

Authors:

Volume:

Pagination:

Issue:

Journal:

PMID:

URL:

DOI:

Keywords:

Abstract:

Go back to Resources

HSV-1 and HSV-2 seroprevalence in the united states among asymptomatic women unaware of any herpes simplex virus infection (Herpevac Trial for Women).

Go back to Resources

HSV-1 and HSV-2 seroprevalence in the united states among asymptomatic women unaware of any herpes simplex virus infection (Herpevac Trial for Women).

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial.

Go back to Resources

Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Hepatitis E infection in HIV-infected liver and kidney transplant candidates.

Go back to Resources

Hepatitis E infection in HIV-infected liver and kidney transplant candidates.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Assessment of congenital anomalies in infants born to pregnant women enrolled in clinical trials.

Go back to Resources

Assessment of congenital anomalies in infants born to pregnant women enrolled in clinical trials.

Authors:

Secondary:

Volume:

Pagination:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 66
  • Page 67
  • Page 68
  • Page 69
  • Current page 70
  • Page 71
  • Page 72
  • Page 73
  • Page 74
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to
Emmes Group

Delivering Global Health
Impact Through People,
Science and Technology

Main navigation
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
    • Veridix - Tech & AI
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us

Copyright ©, The Emmes Company, LLC

Footer
  • Cookie Policy
  • External Privacy Notice
  • FCOI
  • Emmes EU-U.S. Data Privacy Framework
  • Purchasing Terms and Conditions